Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
European Society of Cardiology #HFA Heart Failure Policy Network GICC SFC SFC - Socit Franaise de Cardiologie Kevin Damman Guillaume Baudry Jan Biegus To view or add a comment, sign in AstraZeneca is joining the cardiology community at the European Society of Cardiology congress 2025 to discuss the latest innovations in reducing the global burden of cardiovascular, renal and metabolic (CVRM) diseases which drove around 21 million deaths in 2021 alone
Yes, certain GLP-1 receptor agonists (liraglutide, injectable semaglutide and dulaglutide) have demonstrated cardiovascular benefits in major trials, including reduced risk of heart attack, stroke and cardiovascular death in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors
Contact us if youd like to request reuse of a visual asset
Tumpa JJ, Hayder QUA, Maisa NS, Islam MN
Weve been talking a lot about GLP-1 this year
